非离子表面活性剂逆转肿瘤细胞多药耐药性的机制  

Study on the reversal of cancer cell's multidrug resistance by non-ionic surfactant and its mechanism

作　　者：武建毅[1] 刘岽[1] 唐亮[1] 谈立松[1] 

机构地区：[1]上海市肺科医院免疫治疗科,上海200433

出　　处：《实用医药杂志》2007年第1期87-88,91,共3页Practical Journal of Medicine & Pharmacy

摘　　要：目的探讨非离子表面活性剂聚氧乙烯醚﹑聚乙二醇300﹑曲拉通X100对肺癌耐药细胞A549/DDP(耐顺铂)多药耐药性的逆转及其机制。方法用四氮唑盐(MTT)法进行体外耐药逆转实验,Westernblot检测P-gp(P-糖蛋白)蛋白的表达。结果①合用非离子型表活剂前后,A549/DDP对化疗药物阿霉素、顺铂、丝裂霉素、5-氟尿嘧啶、依托泊甙和长春新碱的敏感性显著增加(各组都为P<0.01);②三种非离子型表面活性剂能抑制P-gp蛋白的表达。结论三种非离子表面活性剂具有逆转A549/DDP耐药性的作用,逆转机制与其抑制P-gp蛋白的表达有关。Objective To discuss whether the non-ionic surfactant （CremophorEL, PEG300, TfitonX- 100）can reverse the mihidrug resistance （MDR） of the lung cancer cell strian A549/DDP or not and their mechanism. Methods The reversing drug resistance was studied by MTT, expression of P-gp was detected by Western blot.Results （1）MTT cytotoxic assay revealed that the sensitivities of A549/DDP cells to chemotherapy drugs were significant changed according to presence or absence of non-ionic surfaetant （P〈0.01）; （2）The three non-ionic surfaetant can inhibit expression of p-gp.C0nclusion The three non-ionic surfaetant can reverse the MDR of the lung cancer cell stfian A549/DDP,inhibiting expression of p-gp maybe its mechanism.

关 键 词：表面活性剂 肺癌 A549/DDP 多药耐药 P-GP 

分 类 号：R734.2[医药卫生—肿瘤]